To include your compound in the COVID-19 Resource Center, submit it here.

Gruenenthal's cebranopadol meets Phase III pain endpoint

Gruenenthal Group (Aachen, Germany) said once-daily cebranopadol ( GRT6005) met the primary endpoint

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE